Cabozantinib Active in Heavily Treated Bladder Cancer

(MedPage Today) -- Single-agent cabozantinib (Cabometyx, Cometriq) was well tolerated and showed activity in heavily pretreated metastatic bladder cancer patients with platinum-refractory disease, a phase II trial found.
Among 42 evaluable patients...